SELLAS Life Sciences
26 hedge funds and large institutions have $11.3M invested in SELLAS Life Sciences in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
88% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $1.05M
18% more capital invested
Capital invested by funds: $9.59M → $11.3M (+$1.69M)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.28% less ownership
Funds ownership: 10.91% → 10.64% (-0.28%)
4% less funds holding
Funds holding: 27 → 26 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prelude Capital Management
New York
|
+$182K |
| 2 |
State Street
Boston,
Massachusetts
|
+$80.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.1K |
| 5 |
D.E. Shaw & Co
New York
|
+$17.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$192K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$161K |
| 3 |
VF
Virtu Financial
New York
|
-$77K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$62.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$59.3K |
SLS Hedge Fund Activity: Q1 2022 in Review
26 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2022, worth a combined $11.3M — up 18% from $9.59M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SLS and 4 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 8 added.
The largest buyer was Prelude Capital Management, opening a new position worth an estimated $182K. The largest seller was Morgan Stanley, cutting an estimated $192K.
- 26 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2022, down from 27 in Q4 2021.
- Funds reported $11.3M of SELLAS Life Sciences stock for Q1 2022, up 18% quarter-over-quarter.
- 4 funds opened new SELLAS Life Sciences positions in Q1 2022 and 5 closed out, a net change of -1 holder.
- The largest SELLAS Life Sciences buyer in Q1 2022 was Prelude Capital Management, an estimated $182K added.
- The largest SELLAS Life Sciences seller in Q1 2022 was Morgan Stanley, an estimated $192K sold.
Based on aggregated 13F filings for Q1 2022.